Skip to search formSkip to main contentSkip to account menu

Folotyn

National Institutes of Health

Related topics

Related topics

2 relations
2 ML Pralatrexate 20 MG/ML Injection [Folotyn]

Broader (1)

Pralatrexate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Belinostat for Peripheral T-Cell Lymphoma
the peripheral t-cell lymphomas (ptCLs) are a diverse group of mature t-cell neoplasms that typically display aggressive clinical… 
Review
2012
Review
2012
Pralatrexate (Folotyn).
T-cell lymphoma accounts for 10% to 15% of all cases of non-Hodgkin lymphoma in the United States (approximately 5000 to 6000… 
Review
2011
Review
2011
Efficacy of Short Oral Leucovorin Rescue (SOLR) In Managing Recurrent Pralatrexate (Folotyn) Induced Mucositis (RPIM) Despite Dose Reduction
Abstract 4745 Mucositis is a frequent complication experienced by patients receiving weekly Pralatrexate, an antifolate agent… 
2010
2010
Pralatrexate injection (Folotyn): Folate analogue metabolic inhibitor approved for treatment of relapsed or refractory peripheral T-cell lymphoma
New molecular entity: Pralatrexate injection (Folotyn) was approved on September 24, 2009, for the treatment of patients with… 
2010
2010
Pralatrexate in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL): Relationship between response and survival.
8054 Background: Pralatrexate (FOLOTYN) is a targeted antifolate designed for preferential uptake and accumulation in tumor cells… 
2010
2010
Pralatrexate (Folotyn) for peripheral T-cell lymphoma.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)